
**Reviewer’s Comments**

****

**Screening Study forFormulation Variables in Preparation and Characterization of Candesartan Cilexetil Loaded Nanostructured Lipid Carriers**

**ABSTRACT**

The current study inspects the screening of the formulation components further, evaluates the quality issues of the nanostructured lipid carriers (NLCs) for the antihypertensive drug as Candesartan Cilexetil (CC). The sequence screening of all excipients required for the preparation of NLCs should be performed.Firstly, the solubility of CC in different solid and liquid lipids is the major parameter for the selection of the best one. Precirol® ATO 5, Compritol ® 888 ATO andGlycerylMonostearate (GMS) were showed the maximum solubility of the CC (1000 ± 4.12 mg, 1500 ± 4.15 mg and 1750 ± 3.16 mg), respectively. Hence, they were selected as the solid lipids for the development of NLCs. Liquid lipids Transcutol® HP (30 ± 2.21 mg/ml), Labrasol® ALF (25 ± 1.32 mg/ml) and CapryolTM 90 (18 ± 1.34 mg/ml) were observed to have good affinity for the drug on systematic screening of different liquid lipids. However, Precirol® ATO 5 was found to hasgood physical compatibility with Transcutol® HP,Compritol ATO 888 was found to hashighphysical miscibility with Labrasol® ALF and last GMS was appeared in good affinity and compatibly with CapryolTM 90. Hence, the following binary lipid mixtures (Precirol® ATO 5 - Labrasol® ALF), (Compritol® 888 ATO - Transcutol® HP) and (GMS - CapryolTM90)wereselected for the preparation of NLCs. The liquid–solid lipid mixture in the ratio up to 30:70 was observed to have sufficient melting point (55-59 ◦C). LutrolF-68, Lutrol F-127, Cremophore EL and Cremophore® RH. In addition to, the combination of(Lutrol® F68:Cremophore® EL)and (Lutrol® F127: Cremophore® RH) were selected as the main surfactants for the preparation of NLCs formulations because of its good emulsification efficacy and homogeneity for the solid-liquid lipid mix. The prepared formulationswereinvestigated for the different quality issues. All designed formulations observed in nanometer size of particles ranged from (408.9 ± 11.5 to 114.6 ± 8.3 nm) with high encapsulation efficiency around 99%.Also, the obtained results revealed that the ZP of the various formulations was consistently negative surface charge in between ((-13 ±2.3 to27.3 ± 3.7 mV). Finally, formula number nine of CC (CC-NLC9) which composed of GMS (solid lipid), CapryolTM 90 (liquid lipid) and Lutrol® F127: Cremophore® RH (surfactants combination) was selected as the best formulation after the rank order for further investigations in the next work.

Keywords: Candesartan Cilexetil,Encapsulation efficiency, In-vitro release, Solid lipid, Nanostructured lipid carriers.

**1. INTRODUCTION**

Candesartan Cilexetil (CC) is prodrug of candesartan, angiotensin II type 1 (AT1) receptor antagonist, widely used in the management of hypertension and heart failure1,2. Candesartan Cilexetil is radiallyhydrolyzed to active form Candesartan during absorption from gastro intestinal tract3,4.

Candesartan Cilexetilowngreatdrawbacks which influence on its oral efficacy and therapeutic applicationsuch as very low aqueous solubility and first-pass metabolism. Consequently, it has very low oral bioavailability not exceed 15%2,4–8.

To avoidpreviously mentioned drawbacks and to enhance oral bioavailability, lipid–based drug delivery systems like nanostructured lipid carrier (NLCs)can be employed. nanostructured lipid carrier (NLCs) canimprove the lymphatic transport of the lipophilic drugs as CC and hence, increase its oral bioavailability 9–11.

Nanostructured lipid carriers (NLCs) composed of both solid and liquid lipids in certain proportion. Therefore, they offer various advantages over solid lipid nanoparticles (SLN) such as higher encapsulation efficiency, smaller size and low polymorphic changes11,15–17

Generally, nanostructured lipid carriers (NLCs) are nano-drug delivery carrier, which own the advantages of polymeric nanoparticles, emulsion, and liposomes.Furthermore, (NLCs) are essentially composed of a biocompatible lipid core with entrapped lipophilic drugs and surfactant at the outer shell.

The major aim of this workwas to select aproper excipient for the development of NLCs using Candesartan Cilexetil (lipophilic anti-hypertensive agent) as a model drug. The screening studies were performed to select the appropriate one of solid lipid, liquid lipid and surfactant. Also, investigation of physical compatibilities of solid lipid with liquid lipid and the ratios of themwere evaluated. Furthermore, the physical characterization and quality issues of developed formulations were described and determined.

Therefore, this study can offer the sequence steps for the development of NLCs and evaluation of their quality characteristics.

**2. Materials and methods**

The active CandesartanCilexetil (CC) wasobtained as a gift fromMEMPHIS, El-Amirya – Cairo –EGYPT.

Compritol**®** 888 ATO (glyceryldibehenate), Precirol**®** ATO 5 (Glyceroldistearate type I), Maisine**®** CC (glycerylmonolinoleate), Labrafac**TM** PG (propylene glycol dicaprylate/ dicaprate), Labrafac**TM** CC (caprylic/ caprictriglycerides), Labrafac**TM** Lipophile WL 1349 (medium-chaintriglycerides), Cpryol**®** 90 (propylene glycol monocaprylate type II), Lauroglycol**®** FCC (propylene glycol monolaurate type I), Labrasol**®** ALF (caprylocaproyl macrogol-8-glycerides), Gelucire**®** 44/14 (lauroyl macrogol-32 glycerides), Gelucire**®** 43/01 (mixtures of mono, di and triglycerideswith PEG esters of fattyacids), Gelucire**®** 39/01 pellets (Glycerol esters of saturated C12-C18 fattyacid ester), Transcutol**®** HP (Highlypurifieddiethylene glycol monoethylether), Labrafil**®** M 1944 CS (oleoyl macrogol-6 glycerides), Labrafil**®** M 2125 CS (linoleoyl macrogol-6-glycerides, corn oil PEG-6-ester), Peceol**TM**(glycerylmonooleate), and Labrafil**®** M 2130 CS (lauroyl macrogol-6-glycerides) werekindlyprovided as a gift samplesfromGattefosse (France).

Glycerylmonostearate (GMS), Stearicacid, Oleicacid, Soybeanoil, Pluronic® F68 (polyoxyethylene-polyoxypropylene (150: 29) block copolymer), Pluronic® F127, Tween® 80 (polyoxyethylene (20) sorbitanmonooleate), Tween® 40 (Polyoxyethylenesorbitanmonopalmitate), Carboxymethylcellulose (CMC).

Phospholipon® 90 G (soyphosphatidylcholine) wasgiven as a gift fromLipoid, Ludwigshafen (Germany).

Cremophor**®** RH 40 (polyoxyl- 40- hydrogenated castor oil) and Cremophor**®** EL (polyethoxylated castor oil) weresuppliedfrom BASF (Germany).

Sodium hydroxide, potassium dihydrogenorthophosphate, Potassium Chloride and Hydrochloricacid (HCL) weresupplied by El-Nasr Pharm. Chem. Company, Cairo (Egypt).

Membrane filter (0.45 µm) Millipore Iberica S.A.U. ; Madrid (Spain).

Methanol and Acetonitrile HPLC grade werepurchasedfrom Sigma Aldrich (USA).

All the above materials were in analytical grade and were used without further purification.

**2.1. Selection of solidlipid**

The solid lipids screening was carried out by quantification of the saturation solubility of CC in different solid lipids which were determined by the test tube method. Precisely weighted amount of the CC (100 mg) putted in the test tube then the solid lipid was added in increments of (250 mg) to the test tube which could be heated to 4-5°C above the melting point of the solid lipid by saving in a controlled temperature water bath (Water path 4050, Romo, Cairo, Egypt). The quantity of solid lipids required to solubilize the drug in the molten state was recorded. The full dissolution state was completed by the formation of a clear, transparent solution. 18–20.

**2.2. Selection of liquidlipid**

Screening of liquid lipids were achieved by determination of saturation solubility of CC in various oils which was performed by adding an excess amount of drug in small glass vials contain fixed volume (5 ml) of different liquid lipids. The vials were strictly closed and incubated in adjusted mechanical shaker (Oscillating thermostatically controlled shaker, Gallent Kamp, England) for 72 h at 37◦C with continuous agitation at 100 rpm 14,21–24. Then the mixtures of liquid lipids and CC were centrifuged at high speed using (Biofuge Primo centrifuge maximum 17.000 rpm, England) centrifuge at 10,000 rpm for 15 min. The supernatant was separated and dissolved in an appropriate amount of methanol and the drug solubility was determined spectrophotometrically using UV-Vis spectrophotometer (Ultraviolet spectrophotometer, Shimadzu 1800, Japan) at λ 254nm.

**2.3. Physical compatibility of solid and liquidlipid**

The miscibility of Selected Solidlipids and liquid lipids which possess the maximumafﬁnityforthedrug could be achieved. Constant ratio 1:1 of solid lipids and liquid lipids were mixed and melted in different glass tubes. The molten binary lipid mixture was permitted to solidify at room temperature. After that, the glass tubes were determined visually for the absence of divided layers in congealed lipid mass. Furthermore, the miscibility between solid lipid and liquid lipid was inspected by smearing a cooled sample of congealed lipid mixture onto a filter paper, followed by visual observation to clear the presence of any residue of oil on the filter paper. A binary mixture distinguished a melting point over 43 oC which did not reveal any residue of oil droplets on the filter paper was selected for the development of CC – loaded NLCs 11,24–26

**2.4. Selection of a binary lipid phase ratios**

The ratio of selected solid lipids and liquid lipids was determined based on the meltingpointofthe binary lipid mixture.Selectedsolidandliquid lipids were blended in the ratio varying from 90:10 to 10:90, then the binary Lipid mixtures were exhibited to be melted and stirred at 200 rpm for 1 h at 5°C above the melting point of solid lipid using hot plate magnetic stirrer (Magnetic stirrer, Wise-stir, Model MSH-20D, Hot plate stirrer, Korea). Then left to solidify at room temperature. The capillary method was used to determine the melting points of the congealed lipid mixtures. 27,28.

**2.5. Selection ofsurfactant**

The surfactant used for fabrication of NLCs should be screened selected depending on its ability to emulsify solid-liquid binary lipid mixture. binary lipid mixture(100mg)wasdissolvedin3mLofmethylenechlorideandaddedto10mLof 5%surfactantsolutionsthen stirred by applyingmagneticstirrer.The organiclayerwasevaporatedat40◦Candtheremainingsuspensionsweredilutedwith10-fold distilled water. The transmittance percent of the resultant sampleswasdeterminedusingUV-Visspectrophotometerat510nm 22,24,29.

**2.6. Fabrication of nanostructured lipid carriers (NLCs)**

CC nanostructured lipid carriers (CC-NLC) were prepared by hot homogenization - ultrasonication technique but with some few modifications. Briefly, a weighted amount of selected solid-liquid binary lipids mixture (5% w/v) was melted at 5 °C above the melting point of solid lipid. A known concentration of CC (5 % w/v of lipids) was dissolved in the prepared oil phase (5 % w/v mixture of solid and liquid lipid). The aqueous phase containing selected surfactant (2.5 % w/v) was heated to the same temperature was added drop by drop to the lipid phase under magnetic stirring at 1500 rpm for 5 min. After that, homogenization of the resultant pre-emulsion was performed at high speed of mixing about 20,000 rpm using an Ultra-Turrax T25 homogenizer (WiseMix™ HG15A, Daihan Scientific, Seoul, Korea) for 10 min 27,30–32. The resultant o/w nanoemulsions were subjected to probe sonication (ultrasonic processor, GE130, probe CV18, USA) at 60 % amplitude for 10 min. The obtained NLC dispersion was left beside to reach room temperature.

**2.7. Physicochemical characterization of CC-NLCs**

**2.7.1. Particle size and polydispersity index**

The meandiameter and polydispersity index of particle of nanostructuredlipid carriers loadedwith CC wasdeterminedusing a Zetasizer Nano-ZS (Malvern Instruments, Worceshtire (UK), equippedwith a 10 mW He-Ne laser employing the wavelength of 633 nm and a back-scattering angle of 90° at 25 °C. Before Photon correlationspectroscopic (PCS) analysis, CC-NLCs formulations shouldbedilutedwith a certain amount of double-distilled water (1:200) to getappropriatescatteringintensity. The analysis, of Particle size wasdeterminedusing Mie theorywith the refractive index and absorbance of lecithin at 1.490 and 0.100, respectively33–36

**2.7.2. Zeta potential analysis**

The zeta potential of NLC formulations was measured via electrophoretic mobility measurements using a Zetasizer Nano-ZS (Malvern Instruments, Worceshtire (UK). The zeta potential was calculated by applying the Helmholtz–Smoluchowski equation (n = 3) 34,37.

**2.7.3. Encapsulation efficiency (EE) and loading capacity (LC)**

The encapsulation efficiency and loadingcapacity of CC into NLC formulations weremeasured by the indirect method by measuring the concentration of the free CC. Initially, 2 ml of NLCs formulations werecentrifuged at 100,000 rpm for 1 h at 4 ◦C to evaluate the unentraped CC usingcoolingultracentrifuge (Beckman Instruments TLX-120 Optima Ultracentrifuge) 38–41. The aqueous layer wasaspirated and filteredusing Millipore® membrane (0.2 μm) and dilutedwith an appropriateamount of methanol and measured by UV-Vis spectrophotometer (Shimadzu, the model UV-1800 PC, Kyoto, Japan) at 254 nm to measure the free amount of CC. Consequently, encapsulation efficiency and loadingcapacity of CC intoNLCsweredeterminedthrough the followingequations

EE% = [(weight of initial drug - weight of free drug) / (weight of free drug)] X 100,

LC% = [(wt. of drug in nanoparticles) / (wt. of nanoparticles)] X 100.

**2.7.4. *In-vitro* drug release study**

The *in vitro* release of CC from CC suspension and CC-NLCs was performed by a dialysis bag diffusion technique.The receptor compartments consist of the following release media: 500 ml Hydrochloric acid solution (0.1 N) of pH 1.2 and phosphate buffer solution (PBS) of pH 6.8 and again, in the same previous media but with addition Polysorbate 20 (0.35%–0.7%w/w) to confirm more achieve sink conditions of dissolution media 42–44. The donor compartment is cellulose membrane dialysis bags (MWCO‑12 000, Sigma, USA) were soaked in dissolution media overnight prior experiment. One milliliter of freshly prepared CC‑NLC and CC suspension (equivalent to 2.5 mg of CC) were diluted with 5 ml of dissolution media and which tightly closed from two sides by a thermo-resistant thread. The bags were immersed in the Dissolution apparatus, (six-spindle dissolution tester, Pharmatest, type PTWII, Germany) automatically adjusted at 37 ± 2 °C and 100 rpm. Two-milliliter sample was aspirated at a predetermined time interval (0.5, 1, 2, 4, 6, 8, 10, 12 and 24 h) and the same volume of media was added to maintain sink condition. The release of free CC from NLC was compared to that from suspension. The aspirated samples were measured using UV-Vis spectrophotometer at 254 nm.

**3. RESULTS and DISCUSSION:**

**3.1. Selection of Solid Lipid**

The efficient solubility of the drug in the solid lipid reflects the capacity of NLC formulations to accommodate high amount of specific drug 45. initially, Candesartan Cilexetil (CC) solubility in various solid lipids should be performed to select the appropriate ones, which allowed accommodation of high amount of the drug leading to maximizing an essential qualification of a carrier system as the loading capacity and encapsulation efficiency of the prepared NLC formulations.

Figure (1) represents the solubility of CC in different solid lipids. The experiments with solid lipids demonstrated that the affinity of CC to solid lipid was in order ofGelucire® 44/14<Precirol® ATO 5 <Compritol ® 888 ATO <Glyceryl Mono Stearate (GMS) <Stearic acid <Labrafil® M 2130 CS<Gelucire® 39/01<Gelucire® 43/01 where,Gelucire® 44/14, Precirol® ATO 5, Compritol® 888 ATO and Glyceryl Mono Stearate (GMS), showed higher CC solubilizing ability, with solid lipid values per 100 mg of CC (w/w) of (750 ± 3.11 mg, 1000 ± 4.12 mg, 1500 ± 4.15 mg and 1750 ± 3.16 mg), respectively. These results related to the imperfect structure of matrix of Gelucire® 44/14, Precirol® ATO 5, Compritol® 888 ATO and Glyceryl Monostearate (GMS) molecules, which are formed due to its chemical nature (mono-, di-, and triglyceride contents) and its composition that containing different length of chain of fatty acid that offer loosely porous structural features that make the drug easier to modify and more soluble 46–48. Gelucire® 44/14 is Polyoxylglycerides mixture 49, Precirol® ATO 5composed of mixture of palmitostearate glyceride and Compritol® 888 ATO composition is mixture of behenate glyceride;50 while Glyceryl Monostearate (GMS) is mixture of variable proportions of glyceryl monostearate and glyceryl monopalmitate49.

The variety of Precirol ATO 5®fatty acid (C 16 and C18) content with sub­sequent loosely porous structure and its higher relative monoglycerides content in between different solid lipids used (more lipid monoglyceride, more lipid polarity) 48,51 In addition, monoglycerides possess emulsification properties 52 which can also improve the drug solubility, such explain the potentiality of Precirol ATO 5® to solubilize Candesartan Cilexetil than Compritol® 888 ATO than GMS.

Stearic acid, Labrafil® M 2130 CS, Gelucire® 39/01, Gelucire® 43/01 proved to be lower CC solubilizing ability, with solid lipid values per 100 mg of CC (w/w) of (2000 ± 3.14 mg, 2000 ± 5.12 mg, 2500 ± 3.15 mg and 2750 ± 4.13 mg), respectively, than the above mentioned ones. So, the following three solid lipids, Precirol® ATO 5, Compritol® 888 ATO and GMS selected to be used as lipid core for the preparations of CC-NLCs in this study after discarding of Gelucire® 44/14 because the addition of Gelucire®44/14 to liquid lipid reduces the melting point of NLCs formulations which was not appropriate to be administered orally 23,53–55..

**3.2. Selection of Liquid Lipid**

Proper dissolvability of CC in Liquid Lipid is basic for the successful formulation of nanostructured lipid carrier as well as encapsulation efficiency was directly influenced by solubility of the drug in liquid lipid. Screening of liquid lipids was evaluated depending on the solubility of CC in different liquid lipids 5,51,56. Also, higher drug solubility in the oil phase brings down the necessities of surfactants in this way limiting their toxic impacts 56.

The solubility of CC in various liquid lipids were showed in figure (2).

It was evident that CC revealed highest solubility in peppermint oil (48 ± 2.14mg/ml), Transcutol® HP (30 ± 2.21 mg/ml), Labrasol® ALF (25 ± 1.32 mg/ml) and CapryolTM 90 (18 ± 1.34 mg/ml) and the least solubility was observed in LabrafacTM PG (1.1 ± 0.97 mg/ml), LabrafacTMLipophil WL 1349 (0.166 ± 0.81 mg/ml) and LabrafacTM CC (0.087 ± 0.65 mg/ml). The relatively high solubility of (CC) in peppermint oil (48 ± 2.14 mg/ml) may be attributed to the composition mixture of peppermint oil with various alcohols, ketones and terpenes (menthol, menthone, 1,8-cineole, methyl acetate, methofuran, isomenthone, limonene, b-pinene, a-pinene and pulegone) 57 that might be aided in solubilization of CC through interaction with one or more of the functional groups of CC (such as –NH and –C=O). Furthermore, surface active properties of components of peppermint oil (HLB = 12.3) 58.

The solubilization ability of Transcutol® HP (30 ± 2.21 mg/ml), Labrasol® ALF (25 ± 1.32 mg/ml) and CapryolTM 90 (18 ± 1.34 mg/ml) for CC was attributed to their intrinsic self-emulsifying property and their chemical structure (PEG-medium chain triglycerides) because of the affinity of a broad range of hydrophilic and lipophilic drug molecules to be encapsulated into lipid carriers, increased with PEG-glycerides than that glycerides free from PEG moieties such as (LabrafacTM PG, LabrafacTMLipophilandLabrafacTM CC) due to their known surfactant properties 39,59.

The high solubilizing effect of Transcutol® HP for CC is consistent with Cirri et al., 2018 29. Furthermore, presence of Caprylic acid (C8) in oil composition had great impaction on drug solubility, where the oils of the more Caprylic acid content were found to be the higher solubilizing one for drug such as (Caprylic acid content in Labrasol® ALF and Capryol 90) are 80 and 90%, respectively, 60. This phenomenon may be attributed to the Caprylic acid polarity making it more efficient solubilizing one for the poorly water-soluble drug. Thus, Transcutol® HP, Labrasol® ALF and CapryolTM 90 were selected as a liquid lipid for further investigation because of the high solubilizing extent of CC after discarding of peppermint oil due to the low of its flashpoint (66.1°C) than the temperature that needed during the formulation preparation process.

**3.3. Physical Compatibilities between Solid lipid and Liquid lipid**

An essential for the improvement of a stable NLC development and permits taking into account that the fluid lipid is completely entrapped inside solid lipid matrix thus, physical compatibility between solid lipids and liquid lipids must be achieved 61,62. All three selected solid lipids (Precirol® ATO 5, Compritol® 888 ATO and GMS) were further evaluated for the physical compatibility with three selected liquid lipids (Transcutol® HP, Labrasol® ALF and CapryolTM 90) by applying visual and filter paper examination. The obtained results indicate that (Precirol® ATO 5 - Transcutol® HP) and (Precirol® ATO 5 - CapryolTM 90) mixtures showed phase separation and residue of liquid oil droplets on filter paper indicating formation of inhomogeneous mixtures (data not shown). The reduction in the melting temperature of the combined lipid mixtures was the reason for such observation.

On the other hand, no presence of more than one layer was observed in the solidified mass and no residue of liquid lipid droplets on the filter paper of (Precirol® ATO 5 - Labrasol® ALF) mixture indicate that formation of homogenous mixture. These results are consistent with S. Doktorovov et al 2010 59,63. However, (Compritol® 888 ATO - Labrasol® ALF) and (Compritol® 888 ATO - CapryolTM 90) mixtures also showed phase separation and presence of liquid oil droplets on filter paper indicating formation of inhomogeneous mixtures. Such an observation could be attributed to the same previous reason mentioned above.

On the other side, there was no separation was showed in the congealed mass and no residue of liquid oil droplets on filter paper of (Compritol® 888 ATO - Transcutol® HP) mixture indicate that formation of homogenous mixture. While, GMS as solid lipid showed good miscibility and homogeneity with all three selected liquid lipids (Transcutol® HP, Labrasol® ALF and CapryolTM 90). Therefore, based on the screening study of the solid and liquid lipids for CC and physical compatibility between two types of lipids, (Precirol® ATO 5 - Labrasol® ALF), (Compritol® 888 ATO - Transcutol® HP) and (GMS - CapryolTM 90) mixtures were selected as solid and liquid lipids, respectively for further investigation. Since Precirol® ATO 5 is one of three selected solid lipids has a high affinity for the CC was found to has also good compatibility for Labrasol® ALF liquid lipid. While Compritol® 888 ATO sloid lipid has a high affinity for CC was found to has good compatibility for Transcutol® HP liquid lipid and GMS solid lipid has a high affinity for CC was found to has good compatibility for CapryolTM 90 liquid lipid while the remained lipids were excluded from further designing of the formulation.

**3.4. Determination of the SL: LL ratios using melting point technique**

solid-liquid lipids proportion was chosen with the goal to have enough drug loading capacity with a legitimate liquefying point to keep up the solid-semisolid uniformity of the particles at room temperature. As (Transcutol® HP, Labrasol® ALF and CapryolTM 90) were seen to have good drug solubilization limit, a higher proportion of (Transcutol® HP, Labrasol® ALF and CapryolTM 90) as liquid lipids could be helpful for the higher drug encapsulation 24. In any case, at the same time, the consistency of the (solid-liquid) lipids blend can't be undermined. It was seen that the (solid-liquid) lipids blend in the proportion up to 70:30 were having an adequate melting point (55 – 59◦C) (data not shown). Furthermore, the increment of liquid lipid concentration, the melting point of the blends were beneath the ideal level. In addition, 70:30 the most appropriate and common ratio and widely applied by most previous related studies 37,64–67. Consequently, 70:30 was chosen as the proper preparing ratio for the solid-liquid lipid mixture in all NLC formulations.

**3.5. Screening study of surfactants: assessment of dispersion properties**

The most important character for surfactant selection is the ability and capacity of surfactant to emulsify the produced emulsion with keeping its stability. A higher transmission rate is consistent with smaller particles and therefore greater emulsification. 22. Furthermore, The surfactant plays a necessary role in stabilization of NLC by decreasing the interfacial tension between the aqueous phase and the lipid phase of nanoemulsion and thus inhibits coalescence and agglomeration of particles 39,68.

As depicted in the table (1). results revealed that Lutrol® F68 showed maximal emulsification capacity for binary lipids of three selected lipid mixtures (Precirol® ATO 5 - Labrasol® ALF), (Compritol® 888 ATO - Transcutol® HP) and (GMS - CapryolTM 90)where (98.106 ± 5.3, 97.324 ± 7.2 and 98.685 ± 5.2% transmittance), respectively. Followed by Lutrol® F127 (97.972 ± 8.1, 95.079 ± 1.4 and 95.004 ± 8.1 % transmittance). Then, Cremophore® EL (94.756 ± 3.3, 89.438 ± 1.3 and 86.475 ± 5.3 % transmittance) and last Cremophore® RH (81.847 ± 9.1, 82.680 ± 6.3 and 78.185 ± 6.7% transmittance).

On the other hand, binary selected lipid mixtures mentioned above exhibited poor emulsification and formed turbid nanoemulsion with Phospholibon® (19.890 ± 7.3, 10.350 ± 4.3 and 30.989 ± 8.3 % transmittance), respectively.The transmittance percentage which clearly distinguished and reflect the ability of surfactants to emulsify and stabilize binary selected lipid mixtures. Where a high percentage of transmittance indicates enough emulsified and stabilized emulsion. This fact is attributed to the hydrophilic-lipophilic balance (HLB) value of surfactant used, which results in high HLB values accompanied by higher transmission lead to smalle particles. 23,69.HLB values of surfactants used in screening studies are in order of lutrol® f68 (HLB = 29) <lutrol® f127 (HLB = 23) <Cremophore® RH (HLB = 14-16) < Tween® 40 (HLB = 15.4) < Tween® 80 (HLB = 15) <Cremophore® EL (HLB = 12-14) <Phospholibon® (HLB = 8) 23,70,71. Phospholibon® was a poor sufficient to emulsify the selected binary lipid mixture because it has a low value of HLB which was not adequate for o/w emulsion formation 72.

Despite there were no major variation of HLB values of the most surfactant used, Cremophore® EL (HLB = 12-14) had high emulsification effect than Cremophore® RH (HLB = 14-16), Tween® 40 (HLB = 15.4) and Tween® 80 (HLB = 15). Apart from HLB value, there were another factor such as the chemical structure of surfactants had a great impaction on the nanoemulsification process. Tween® 80 is derived from polyoxylatedsorbitan and oleic acid. Cremophor® EL is polyethoxylated castor oil, which is a mixture of polyethylene glycol ethers and polyethylene glycol esters of glycerol and ricinoleic acid. Cremophor® EL possesses a branched structure of alkyl chain, whereas Tween® 80 possesses a linear shape structure. The obtained results were in confirmation with Borhade et al 2012, 2008 and Kassem et al 2017 73–75 stated that surfactants whose branched alkyl structure had good emulsification properties on nanoemulsion formation. Therefore, based on the emulsification ability of surfactants for selected binary lipid mixtures, Lutrol® F68, Lutrol® F127, Cremophore® EL, Cremophore® RH, Tween® 40 and Tween® 80 were selected for further investigation as surfactant combination study.

**3.6. Screening study of surfactants combination: assessment of dispersion properties**

From previous literature, it was clearly distinguished that the kind and quantity of surfactant influence the size of the nanoparticles and their storage stability. The quantity of surfactant should be enough to cover the surface of the hydrophobic nanoparticles 39,76. The combination of two or more surface-active agents exhibits to form blended surfactant films at the surface of the particle size. The formed blended surfactant films were produced in sufficient amount to cover the surface of particles successfully and produce nanoparticles with small size as well as keeping storage stability by production of requisite viscosity 22,77–79.

In present art, it was observed in table (2) 1:1 ratio of Lutrol® f127 and Cremophore® RH showed good emulsification ability and promote nanoemulsion stability of first binary lipids mixture (Precirol® ATO 5 - Labrasol® ALF), combination of selected surfactants in ratio as the same previous exhibited poor emulsification properties of second binary lipids mixture (Compritol® 888 ATO - Transcutol® HP) while combination of selected emulsifying agent at the mentioned above ratio (Lutrol® f68 and Cremophore® EL) and (Lutrol® f127 and Cremophore® RH) showed the higher emulsification capability as well as stability of emulsion of third binary lipids mixture (GMS - CapryolTM 90).

The obtained results may be attributed to the same reasons mentioned above under explanation of screening study of surfactants wherein the hydrophilic-lipophilic balance (HLB) value of the surfactant play a great role in this fact 23,70,71. Also, branched alkyl chain structure, as well as the length of hydrophobic chains of surfactants, had a countless effect on the nanoemulsion formation 73–75 as Cremophore® EL and Cremophore® RH.

hence, based on the introduced emulsification study of surfactants, Lutrol® F68 andLutrol® F127 were selected as surfactants for every binary lipid mixture for the preparation of NLC. Addition to (Lutrol® f127: Cremophore® RH) at equal ratio for (Precirol® ATO 5 - Labrasol® ALF) binary lipid mixture and (Lutrol® f68: Cremophore® EL) and (Lutrol® f127: Cremophore® RH) at equal ratio for (GMS - CapryolTM 90) binary lipids mixture as surfactant combination for preparation of NLC.

**3.7. Fabrication of CC-NLCs**

Based on screening and solubility studies, the NLC formulations were designed, formulated and improved using lipid phase composed of Precirol® ATO 5, Compritol® 888 ATO and GMS as solid lipid and Labrasol® ALF, Transcutol® HP and CapryolTM 90 as liquid lipid which were chosen based on CC solubility in the lipid phase. Lutrol® F68, Lutrol® F127, Cremophore® EL and Cremophore® RH as surfactants which constituted the aqueous phase. The concentration of the lipid phase to surfactant was constant at 5% (w/w) and 2.5% (w/w), respectively and the concentration of CC was fixed to 5% (W/W) of the lipid phase. The lipid phase should not be exceedingly beyond 5% w/w. The observations are in line with studies reported by Das et al 2012 and Elbahwy et al 2017 72,80 who discovered that an increased concentration of lipid leads to an enormous increase of particle size. As formulations are designed to be orally used, surfactants have been established at a pleasant 2.5% concentration (w / w) 81. The composition of the formulation is given in the table (3). Preparation of CC-NLCs were performed using homogenization followed by probe sonication technique. the influence of the lipids and surfactants variation on the particle size and the PDI was studied. also, other physical characterization should be achieved for every formulation to select the best one for further investigations.

**3.8. Physicochemical characterization of CC-NLC formulations**

**3.8.1. Particle size, polydispersity index (PDI)**

Determination of physical properties as particle size and PDI are essential for predicting the stability of NLCs formulations.Particle sizing is a significant method for confirming nanosized particle manufacturing. Also, the smallest particle size, the more absorbable and uptake through the gastrointestinal tract. then, efficiently phagocytosed by the reticuloendothelial system. Therefore, the accuracy in particle size evaluation was necessary. Usually, the recommended particle size requisite for transportation through the intestine should not be more than 300 nm 82,83.

As represented in table (4) and figure (3) the observations revealed that all the designed formulations were showed in the nanometer range (<408 nm). It can be concluded that particle size of Precirol® ATO 5 nanoparticles (F1 to F3), Compritol® 888 ATO nanoparticles (F4 and F5) and GMS nanoparticles (F6 to F9) ranged from (280.6 ± 11.8 to 118.6 ± 8.1 nm), (283 ± 9.9 and 196.5 ± 10.2 nm) and (408.9 ± 11.5 to 114.6 ± 8.3 nm), respectively. The obtained results were clearly distinguished that formulations that contain more than one surfactant give the small particle size than that contain one surfactant as in F3 and F9 (118.6 ±8.1 and 114.6 ±8.3 nm) this behavior was attributed to the same reason discussed above under the screening study of surfactants combination. Also, these results were in accordance with the following reported studies 22,77–79,83.

On the other hand, the largest particle size was exhibited in GMS formulations which contain surfactant Lutrol® F68 alone or in combination with other surfactants as in F6 and F8 (408.9 ± 11.5 and 392.1 ± 13.8 nm). This observation may be attributed to the tendency of GMS nanoparticles to form a gel after 24 h storage at room temperature due to polymorphic transitions in GMS after cooling at room temperature. Furthermore, the interaction between GMS and Lutrol® F68. The polymorphic transitions in the lipids after cooling to the room temperature and the interaction between surfactant and lipid are known to cause gel formation and subsequently influence the PS in NLC and SLN dispersions 84,85.

The polydispersity index as an indicator of the size distribution width of the particle. The PI value that reflects dispersion quality typically varies between 0 and 1. Most researchers recognize PI values ≤ 0.3 as optimum values; however, values ≤ 0.5 are also acceptable 86. Table (4) and figure (3) give an overview of the results of polydispersity index measurements. The prepared NLC dispersions had a PI value ≤ 0.35 ± 0.01 due to the preparation method used indicating a homogenous and narrow size distribution of nanoparticles of NLCs.

**3.8.2. Zeta potential (ζ) measurement**

The main parameter which influences the storage stability of colloidal nanocarrier is zeta potential, which measures the nanoparticle's surface charge and provides the repulsion degree between the nanoparticles preventing its agglomeration 87,88. From the factors which mainly influence zeta potential of lipid-based nanoparticles structure of solid and liquid lipid and the medium composition 65,88. Also, it depends on higher steric stabilization and lowers an electrostatic stabilization of nonionic surfactants which perfectly forming a coat around the particles of NLCs. Result in surface coverage of NLC decreases the electrophoretic mobility of nanoparticles and thus lower the zeta potential values 6,36,38,81,89. This phenomenon explains the higher stability of NLC formulations despite having a lower zeta potential value.

Zeta potential values ofall designed formulations are shown in table (4) and represented in figure (4). The results revealed that the ZP of the various formulations was a consistently negative surface charge. ZP values of Precirol® ATO 5 nanoparticles (F1 to F3), Compritol® 888 ATO nanoparticles (F4 and F5) and GMS nanoparticles (F6 to F9) in between (-13 ±2.3 to -­17.8 ± 2.8 mV), (-18.1 ± 2.4 and -18.7 ± 1.7 mV) and (-18.9 ±1.9 to 27.3 ± 3.7 mV), respectively. Due to the non-ionic behavior of used surfactants for stabilization of nanoparticles so, these molecules had not any role in the obtained zeta potential charges. Furthermore, the solid lipids were used in developed NLCs composed of mixture of acylglycerols: Precirol® ATO 5 composed ofglyceryltripalmitostearate (25% - 35%), glyceryl dipalmitostearate (40% - 60%) and glyceryl monopalmitostearate (8% - 22%) 49,90 and Compritol® 888 ATO composed of glyceryl tribehenate (28% - 32%), glyceryl dibehenate (52% - 54%) and glyceryl monobehenate (12% - 18%) 49,88, both of them being glycerol esters of long chain-length fatty acids (C18, C16) and (C22) respectively. So, that they provide neither charge nor polarity that participates to zeta potential. whereas, GMS composed of triacylglycerols (5 – 15%), diacylglycerols (30 – 45%) and monoacylglycerols (40 – 55%) 49. In such a case due to the high content of partial emulsifying glycerides (mono and diglycerides) of GMS and the presence of non-esterified hydroxyl groups of glycerol, this molecule showed some of the polarity that participates to zeta potential.

On the other hand, the liquid lipids were used in developed NLCs composed of diacylglycerol of medium-chain-length fatty acids. Liquid lipids provide the majority impaction and contribute to zeta potential due to its polarity which results from a free hydroxyl group of the glycerol that not subjected to the esterification process and the chain length of the fatty acids. These observations are in line with studies reported by Teeranachaideekul*et al,* 2008and López-García and Ganem-Rondero, 201588,91 which stated that it might be due to presence of liquid lipid at the surface of NLC. Being the melting point of liquid lipid lower than that of the solid lipid, during the fabrication process of NLC, the solid lipid recrystallizing again first, with encapsulating an apart of the liquid lipid inside the solid lipid matrix. Subsequently, the remained amount of liquid lipid was covered the outer layer of formed nanoparticles 59,92*.*

The obtained results can be concluded that GMS nanoparticles (F6 to F9) possessed high zp values than that of Precirol® ATO 5 nanoparticles (F1 to F3) and Compritol® 888 ATO nanoparticles (F4 and F5) this fact can be explained by the following reasons: certain polarity and emulsifying properties of GMS resulted from none esterified hydroxyl group of glycerol and the length of chain of the fatty acids. Another reason was attributed to the negative charged carboxylic groups of MCT (capryolTM 90) which composed mainly monoesters and a small fraction of diesters of caprylic/capric triglyceride. A similar explanation has been reported by Teeranachaideekul et al, 2007 93, these revealed the higher ZP values of GMS nanoparticles than other nanoparticles.

**3.8.3. Entrapment Efficiency, Drug Content and Drug Loading of CC-NLCs**

The quantity of drug encapsulated in the nanoparticles and the drug content in the lipid matrix is a further significant consideration for the optimization of NLC. The quantity of drug encapsulated in the lipid matrix depends on many factors as: the type of lipids used, physicochemical properties of the drug, miscibility and solubility of drug in the molten lipid 94, physical and chemical nature of the lipid matrix and crystalline state of lipid matrix and also surfactant was found to affect encapsulation efficiency 38,46,95.

Encapsulation efficiency and loading capacity of all NLC formulations are showed in the table (5) and demonstrated in figure (5). The entrapment efficiency and drug loading were determined and found to be in between 94.76 ± 2.44 % to 99.80 ± 2.50% and 0.55 ± 0.11% to 5.10 ± 0.19%, respectively. These high entrapment efficiencies and drug loading of CC in NLCs could be attributed to the high lipophilic nature of CC (log p ~ 6.2) which enhance the solubility of CC in various lipids and subsequently easily incorporated into the lipid matrix 6,96. Moreover, the using of a mixture of perfect ordered with less ordered lipids, which caused several crystal defects in lipid matrix and provided much imperfections leading to void spaces in which more drug molecules could be accommodated 14,38,83,96.

It was observed that E.E and LC of CC in Precirol® ATO 5 nanoparticles (F1 to F3) were varied from 98.5 ± 2.70% to 99.8 ± 2.50 and 1.03 ± 0.10 to 1.32 ± 0.21, respectively, in Compritol® 888 ATO nanoparticles (F4 and F5) were varied from 99.04 ±2.35 to 99.30 ± 2.25% and 0.82 ± 0.13 to 0.55 ± 0.11, respectively and in GMS nanoparticles (F6 to F9) also were ranged from 94.76 ± 2.44% to 95.94 ± 3.45% and 3.92 ± 0.31% and 5.10 ± 0.19%, respectively. From the results, it was clearly distinguished that Precirol® ATO 5 nanoparticles (F1 to F3) and Compritol® 888 ATO nanoparticles (F4 and F5) showed higher entrapment efficiency around 99% than that of GMS nanoparticles (F6 to F9) around 95%. Such a fact was attributed to the chemical composition of each one. Where, the imperfect and less ordered matrix structure of Precirol® ATO 5 and Compritol® 888 ATO molecules, which are formed from a combination of mono-, di- and triglyceride that expected to exhibit lower crystallinity and more structure porosity which allows higher solubility and easier accommodation of more drug molecules 23,45. Also, Precirol® ATO 5 is a di-glyceride with two different chain length fatty acids palmitic and stearic acid (C16 and C18); therefore, it is expected to have less ordered lipid network compared to GMS, and thus lead to the more drug molecules could be entrapped 23,47,54. Further, subsequent to cooling, Precirol® ATO 5 and Compritol® 888 ATO recrystallize in a progression of polymorphs. In like manner, with respect to the conditions utilized during the preparation, CC could be homogenously dispersed 38.

Regarding the type of surfactant, it was clearly observed that NLCs formulation prepared using Lutrol® F68 higher E.E. than that prepared using other surfactants. This behavior repeated with every nanoparticle prepared using Lutrol® F68 alone (F1, F4 and F6) or in combination with Cremophore® EL (F8). This fact might be attributed to the high value of the hydrophilic-lipophilic balance of Lutrol® F68 (HLB ~ 29) compared to other surfactants.

**3.8.4 *In-vitro* release study**

In-vitro release study was achieved for all formulations in addition to pure CC suspension. The release condition monitored in 0.1 M HCl (pH 1.2) and PBS (pH 6.8) and at the same conditions with adding tween 20 (0.35%–0.7%w/w) to achieve “sink” conditions during a dissolution test for all formulations 43,97. It was found that all formulations exhibit a lack of drug release within 24 h except CC suspension showed almost complete drug release (100%) within 8 h. As CC had solubilities equal to 11 μg/mL in 0.1 M HCl and 1 μg/mL in PBS (pH 6.8)8,98, the very difficult release of CC results from its poor aqueous solubility and high lipophilicity(log p ~ 6.2). Thus, CC possesses a high affinity to the lipids consequently the drug becomes more entrapped and retained inside the core of the lipid matrix preventing it from the release. Furthermore, the high efficient solubility and compatibility of CC with the lipid components as previously discussed before under screening studies 8,99. These observations are in line with the study reported by Zhang et al 2012 8. Previous studies ascertained that NLCs must be absorbed into the blood or lymphatic system after duodenal administration to rates 100. Consequently, lack of in-vitro release of CC from NLCs suggesting that NLCs could be absorbed via the enterocytes after oral administration, the most sought-after therapeutic effect.which required conformation through employing more investigations in next work.

The rank order was performed for all prepared NLCs formulations (F1 to F9) in order to choose the best formula based on the previously measured characterization as Particle size, polydispersity index (PDI), zeta potential (ζ), encapsulation efficiency and loading capacity of CC-NLCs wherein the formula F9 was chosen as the best formula for further investigations.

**4. CONCLUSION**

Nanostructured lipid carriers (NLCs) are adaptable nanoparticles with multipurpose applications. However, quality and successful incorporation of CC into NLC to develop more efficient formulation based on proper selection of the components and optimization. The current workclarifies a sequence steps for selection of excipients for NLCs by employing simple experiments.

screening studies were performed for whole excipients to select appropriate ones to prepare CC loaded NLCs.

Furthermore, the developed formulations were subjected to physicochemical characterization.The resulted formulations appeared in nanoparticle size with high encapsulation efficiency.

**References**

1. Israili, Z. H. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. *J. Hum. Hypertens.***14**, S73–S86 (2000).

2. Gurunath, S., Nanjwade, B. K. & Patil, P. A. Oral bioavailability and intestinal absorption of candesartan cilexetil: Role of naringin as P-glycoprotein inhibitor. *Drug Dev. Ind. Pharm.***41**, 170–176 (2015).

3. Ferreirós, N., Dresen, S., Alonso, R. M. & Weinmann, W. Hydrolysis and transesterification reactions of candesartan cilexetil observed during the solid phase extraction procedure. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.***855**, 134–138 (2007).

4. Gurunath, S., Nanjwade, B. K. & Patila, P. A. Enhanced solubility and intestinal absorption of candesartan cilexetil solid dispersions using everted rat intestinal sacs. *Saudi Pharm. J.***22**, 246–257 (2014).

5. AboulFotouh, K., Allam, A. A., El-Badry, M. & El-Sayed, A. M. Development and in vitro/in vivo performance of self-nanoemulsifying drug delivery systems loaded with candesartan cilexetil. *Eur. J. Pharm. Sci.***109**, 503–513 (2017).

6. Dudhipala, N. & Veerabrahma, K. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: Characterization, pharmacokinetic and pharmacodynamic evaluation. *Drug Deliv.***23**, 395–404 (2016).

7. Thakkar, H., Desai, J. & Parmar, M. Application of Box-Behnken design for optimization of formulation parameters for nanostructured lipid carriers of candesartan cilexetil. *Asian J. Pharm.***8**, 81 (2014).

8. Zhang, Z., Gao, F., Bu, H., Xiao, J. & Li, Y. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: In vitro characteristics and absorption mechanism in rats. *Nanomedicine Nanotechnology, Biol. Med.***8**, 740–747 (2012).

9. Ravi, P. R., Aditya, N., Kathuria, H., Malekar, S. & Vats, R. Lipid nanoparticles for oral delivery of raloxifene: Optimization, stability, in vivo evaluation and uptake mechanism. *Eur. J. Pharm. Biopharm.***87**, 114–124 (2014).

10. Paliwal, R. *et al.* Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. *Nanomedicine Nanotechnology, Biol. Med.***5**, 184–191 (2009).

11. Mathur, P., Sharma, S., Rawal, S., Patel, B. & Patel, M. M. Fabrication, optimization, and in vitro evaluation of docetaxel-loaded nanostructured lipid carriers for improved anticancer activity. *J. Liposome Res.***0**, 1–15 (2019).

12. Attama, A. A., Momoh, M. A. & Builders, P. F. Lipid Nanoparticulate Drug Delivery Systems: A Revolution in Dosage Form Design and Development. in *Recent Advances in Novel Drug Carrier Systems* 107–140 (2012). doi:10.5772/50486

13. Poonia, N., Kharb, R., Lather, V. & Pandita, D. Nanostructured lipid carriers: versatile oral delivery vehicle. *Futur. Sci. OA***2**, FSO135 (2016).

14. Mendes, I. T. *et al.* Development and characterization of nanostructured lipid carrier-based gels for the transdermal delivery of donepezil. *Colloids Surfaces B Biointerfaces***177**, 274–281 (2019).

15. Rawal, S. & Patel, M. M. Threatening cancer with nanoparticle aided combination oncotherapy. *J. Control. Release***301**, 76–109 (2019).

16. Wa Kasongo, K., Shegokar, R., Müller, R. H. & Walker, R. B. Formulation development and in vitro evaluation of didanosine-loaded nanostructured lipid carriers for the potential treatment of AIDS dementia complex. *Drug Dev. Ind. Pharm.***37**, 396–407 (2011).

17. Muchow, M., Maincent, P. & Müller, R. H. Lipid nanoparticles with a solid matrix (SLN®, NLC®, LDC®) for oral drug delivery. *Drug Dev. Ind. Pharm.***34**, 1394–1405 (2008).

18. Madan, J., Dua, K. & Khude, P. Development and evaluation of solid lipid nanoparticles of mometasone furoate for topical delivery. *Int. J. Pharm. Investig.***4**, 60 (2014).

19. Mandawgade, S. D. & Patravale, V. B. Development of SLNs from natural lipids: Application to topical delivery of tretinoin. *Int. J. Pharm.***363**, 132–138 (2008).

20. Joshi, M. & Patravale, V. Formulation and evaluation of nanostructured lipid carrier (NLC)-based gel of valdecoxib. *Drug Dev. Ind. Pharm.***32**, 911–918 (2006).

21. Gadhave, D. G., Tagalpallewar, A. A. & Kokare, C. R. Agranulocytosis-Protective Olanzapine-Loaded Nanostructured Lipid Carriers Engineered for CNS Delivery: Optimization and Hematological Toxicity Studies. *AAPS PharmSciTech***20**, 1–15 (2019).

22. Rizwanullah, M., Amin, S. & Ahmad, J. Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers. *J. Drug Target.***25**, 58–74 (2017).

23. Khames, A., Khaleel, M. A., El-Badawy, M. F. & El-Nezhawy, A. O. H. Natamycin solid lipid nanoparticles - sustained ocular delivery system of higher corneal penetration against deep fungal keratitis: Preparation and optimization. *Int. J. Nanomedicine***14**, 2515–2531 (2019).

24. Negi, L. M., Jaggi, M. & Talegaonkar, S. Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers. *Int. J. Pharm.***461**, 403–410 (2014).

25. Sinhmar, G. K., Shah, N. N., Chokshi, N. V., Khatri, H. N. & Patel, M. M. Process, optimization, and characterization of budesonide-loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease. *Drug Dev. Ind. Pharm.***44**, 1078–1089 (2018).

26. Gaba, B. *et al.* Nanostructured lipid carrier system for topical delivery of terbinafine hydrochloride. *Bull. Fac. Pharmacy, Cairo Univ.***53**, 147–159 (2015).

27. Cortesi, R. *et al.* Nanostructured lipid carriers (NLC) for the delivery of natural molecules with antimicrobial activity: production, characterisation and in vitro studies. *J. Microencapsul.***34**, 63–72 (2017).

28. Shete, H., Chatterjee, S., De, A. & Patravale, V. Long chain lipid based tamoxifen NLC. Part II: Pharmacokinetic, biodistribution and in vitro anticancer efficacy studies. *Int. J. Pharm.***454**, 584–592 (2013).

29. Cirri, M. *et al.* Design, characterization and in vivo evaluation of nanostructured lipid carriers (NLC) as a new drug delivery system for hydrochlorothiazide oral administration in pediatric therapy. *Drug Deliv.***25**, 1910–1921 (2018).

30. Niamprem, P., Srinivas, S. P. & Tiyaboonchai, W. Penetration of Nile red-loaded nanostructured lipid carriers (NLCs) across the porcine cornea. *Colloids Surfaces B Biointerfaces***176**, 371–378 (2019).

31. Nnamani, P. O., Hansen, S., Windbergs, M. & Lehr, C. M. Development of artemether-loaded nanostructured lipid carrier (NLC) formulation for topical application. *Int. J. Pharm.***477**, 208–217 (2014).

32. Ezzati Nazhad Dolatabadi, J. *et al.* Formulation, characterization and cytotoxicity evaluation of ketotifen-loaded nanostructured lipid carriers. *J. Drug Deliv. Sci. Technol.***46**, 268–273 (2018).

33. Gu, Y., Tang, X., Yang, M., Yang, D. & Liu, J. *Transdermal drug delivery of triptolide-loaded nanostructured lipid carriers: Preparation, pharmacokinetic, and evaluation for rheumatoid arthritis*. *International Journal of Pharmaceutics***554**, (Elsevier B.V., 2019).

34. Wolf, M. *et al.* Monoacyl-phospatidylcholine based drug delivery systems for lipophilic drugs: Nanostructured lipid carriers vs. nano-sized emulsions. *J. Drug Deliv. Sci. Technol.***46**, 490–497 (2018).

35. Li, H., Chen, M., Su, Z., Sun, M. & Ping, Q. Size-exclusive effect of nanostructured lipid carriers on oral drug delivery. *Int. J. Pharm.***511**, 524–537 (2016).

36. Shah, R., Eldridge, D., Palombo, E. & Harding, I. Optimisation and stability assessment of solid lipid nanoparticles using particle size and zeta potential. *J. Phys. Sci.***25**, 59–75 (2014).

37. Marques, A. C., Rocha, A. I., Leal, P., Estanqueiro, M. & Lobo, J. M. S. Development and characterization of mucoadhesive buccal gels containing lipid nanoparticles of ibuprofen. *Int. J. Pharm.***533**, 455–462 (2017).

38. Tatke, A. *et al.* In situ gel of triamcinolone acetonide-loaded solid lipid nanoparticles for improved topical ocular delivery: Tear kinetics and ocular disposition studies. *Nanomaterials***9**, 1–17 (2019).

39. Safwat, S., Ishak, R. A. H., Hathout, R. M. & Mortada, N. D. Nanostructured lipid carriers loaded with simvastatin: effect of PEG/glycerides on characterization, stability, cellular uptake efficiency and in vitro cytotoxicity. *Drug Dev. Ind. Pharm.***43**, 1112–1125 (2017).

40. Tiwari, R. & Pathak, K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: Comparative analysis of characteristics, pharmacokinetics and tissue uptake. *Int. J. Pharm.***415**, 232–243 (2011).

41. Nafee, N., Makled, S. & Boraie, N. Nanostructured lipid carriers versus solid lipid nanoparticles for the potential treatment of pulmonary hypertension via nebulization. *Eur. J. Pharm. Sci.***125**, 151–162 (2018).

42. Gruberová, L. & Kratochvil, B. Biorelevant dissolution of candesartan cilexetil. *ADMET DMPK***5**, 39 (2017).

43. Hassan, H. A., Charoo, N. A., Ali, A. A. & Alkhatem, S. S. Establishment of a bioequivalence- indicating dissolution specification for candesartan cilexetil tablets using a convolution model. *Dissolution Technol.***22**, 36–43 (2015).

44. Lombardi Borgia, S. *et al.* Lipid nanoparticles for skin penetration enhancement - Correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. *J. Control. Release***110**, 151–163 (2005).

45. Vivek, K., Reddy, H. & Murthy, R. S. R. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. *AAPS PharmSciTech***8**, 16–24 (2007).

46. Müller, R. H., Mäder, K. & Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art. *Eur. J. Pharm. Biopharm.***50**, 161–177 (2000).

47. Seyed Yagoubi, A., Shahidi, F., Mohebbi, M., Varidi, M. & Golmohammadzadeh, S. Preparation, characterization and evaluation of physicochemical properties of phycocyanin-loaded solid lipid nanoparticles and nanostructured lipid carriers. *J. Food Meas. Charact.***12**, 378–385 (2018).

48. Kuo, Y. C. & Chung, J. F. Physicochemical properties of nevirapine-loaded solid lipid nanoparticles and nanostructured lipid carriers. *Colloids Surfaces B Biointerfaces***83**, 299–306 (2011).

49. Raymond C Rowe, P. J. S. and M. E. Q. *Handbook of Pharmaceutical Excipients, sixth Edition*. *the Pharmaceutical Press, london* (2009). doi:10.1016/s0168-3659(01)00243-7

50. Abd-Elbary, A., Tadros, M. I. & Alaa-Eldin, A. A. Sucrose Stearate-Enriched Lipid Matrix Tablets of Etodolac: Modulation of Drug Release, Diffusional Modeling and Structure Elucidation Studies. *AAPS PharmSciTech***14**, 656–668 (2013).

51. Kaithwas, V., Dora, C. P., Kushwah, V. & Jain, S. Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability. *Colloids Surfaces B Biointerfaces***154**, 10–20 (2017).

52. Jensen, L. B. *et al.* Corticosteroid solubility and lipid polarity control release from solid lipid nanoparticles. *Int. J. Pharm.***390**, 53–60 (2010).

53. Kasongo, K. W., Pardeike, J., Müller, R. H. & Walker, R. B. Selection and characterization of suitable lipid excipients for use in the manufacture of didanosine-loaded solid lipid nanoparticles and nanostructured lipid carriers. *J. Pharm. Sci.***100**, 5185–5196 (2011).

54. Vivek, K., Reddy, H. & Murthy, R. S. R. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. *AAPS PharmSciTech***8**, 16–24 (2007).

55. Wong, H. L., Bendayan, R., Rauth, A. M., Li, Y. & Wu, X. Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. *Adv. Drug Deliv. Rev.***59**, 491–504 (2007).

56. Parmar, N., Singla, N., Amin, S. & Kohli, K. Study of cosurfactant effect on nanoemulsifying area and development of lercanidipine loaded (SNEDDS) self nanoemulsifying drug delivery system. *Colloids Surfaces B Biointerfaces***86**, 327–338 (2011).

57. Lin, W. *et al.* Chemical Composition and Biological Properties of Essential Oils of Two Mint Species. *Trop. J. Pharm. Res.***12**, 577–582 (2013).

58. Orafidiya, L. O. & Oladimeji, F. A. Determination of the required HLB values of some essential oils. *Int. J. Pharm.***237**, 241–249 (2002).

59. Doktorovová, S., Araújo, J., Garcia, M. L., Rakovský, E. & Souto, E. B. Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC). *Colloids Surfaces B Biointerfaces***75**, 538–542 (2010).

60. Bandivadeka, M. M., Pancholi, S. S., Kaul-Ghanekar, R., Choudhari, A. & Koppikar, S. Self-microemulsifying smaller molecular volume oil (Capmul MCM) using non-ionic surfactants: A delivery system for poorly water-soluble drug. *Drug Dev. Ind. Pharm.***38**, 883–892 (2012).

61. Müller, R. H., Radtke, M. & Wissing, S. A. Nanostructured lipid matrices for improved microencapsulation of drugs. *Int. J. Pharm.***242**, 121–128 (2002).

62. Radtke, M. & Müller, R. H. Nanostructured Lipid Carriers: A novel generation of solid lipid drug drug Carriers. *Pharm. Teachnology Eur.***17**, 1–4 (1991).

63. Liu, Y. *et al.* Nanostructured lipid carriers versus microemulsions for delivery of the poorly water-soluble drug luteolin. *Int. J. Pharm.***476**, 169–177 (2014).

64. Abdolahpour, S. *et al.* Development of Doxorubicin-Loaded Nanostructured Lipid Carriers: Preparation, Characterization, and In Vitro Evaluation on MCF-7 Cell Line. *Bionanoscience***7**, 32–39 (2017).

65. Noh, G. Y., Suh, J. Y. & Park, S. N. Ceramide-based nanostructured lipid carriers for transdermal delivery of isoliquiritigenin: Development, physicochemical characterization, and in vitro skin permeation studies. *Korean J. Chem. Eng.***34**, 400–406 (2017).

66. Elnaggar, Y. S. R., El-Massik, M. A. & Abdallah, O. Y. Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipid nanoparticles. *Int. J. Nanomedicine***6**, 3195–3205 (2011).

67. Scioli Montoto, S. *et al.* Carbamazepine-loaded solid lipid nanoparticles and nanostructured lipid carriers: Physicochemical characterization and in vitro/in vivo evaluation. *Colloids Surfaces B Biointerfaces***167**, 73–81 (2018).

68. Trotta, M., Debernardi, F. & Caputo, O. Preparation of solid lipid nanoparticles by a solvent emulsification--diffusion technique. *Int. J. Pharm.***257**, 153–160 (2003).

69. Bahari, L. A. S. & Hamishehkar, H. The impact of variables on particle size of solid lipid nanoparticles and nanostructured lipid carriers; A comparative literature review. *Adv. Pharm. Bull.***6**, 143–151 (2016).

70. Malkani, A., Date, A. A. & Hegde, D. Celecoxib nanosuspension: Single-step fabrication using a modified nanoprecipitation method and in vivo evaluation. *Drug Deliv. Transl. Res.***4**, 365–376 (2014).

71. Shah, S. M., Jain, A. S., Kaushik, R., Nagarsenker, M. S. & Nerurkar, M. J. Preclinical Formulations: Insight, Strategies, and Practical Considerations. *AAPS PharmSciTech***15**, 1307–1323 (2014).

72. Elbahwy, I. A., Ibrahim, H. M., Ismael, H. R. & Kasem, A. A. Enhancing bioavailability and controlling the release of glibenclamide from optimized solid lipid nanoparticles. *J. Drug Deliv. Sci. Technol.***38**, 78–89 (2017).

73. Borhade, V., Pathak, S., Sharma, S. & Patravale, V. Clotrimazole nanoemulsion for malaria chemotherapy. Part I: Preformulation studies, formulation design and physicochemical evaluation. *Int. J. Pharm.***431**, 138–148 (2012).

74. Borhade, V., Nair, H. & Hegde, D. Design and Evaluation of Self-Microemulsifying Drug Delivery System (SMEDDS) of Tacrolimus. *AAPS PharmSciTech***9**, 13–21 (2008).

75. Kassem, A. M., Ibrahim, H. M. & Samy, A. M. Development and optimisation of atorvastatin calcium loaded self-nanoemulsifying drug delivery system (SNEDDS) for enhancing oral bioavailability: in vitro and in vivo evaluation. *J. Microencapsul.***34**, 319–333 (2017).

76. Manjunath, K., Reddy, J. S. and & V., V. Solid lipid nanoparticles as drug delivery system. *Methods Find Exp Clin Pharmacol***27**, 1–20 (2005).

77. Tan, S. W., Billa, N., Roberts, C. R. & Burley, J. C. Surfactant effects on the physical characteristics of Amphotericin B-containing nanostructured lipid carriers. *Colloids Surfaces A Physicochem. Eng. Asp.***372**, 73–79 (2010).

78. Müller, R. H., Mäder, K. & Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art. *Eur. J. Pharm. Biopharm.***50**, 161–177 (2000).

79. ICI Americas Inc. *time-saving guide to emulsifier selection*. (1976).

80. Das, S., Ng, W. K. & Tan, R. B. H. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): Development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? *Eur. J. Pharm. Sci.***47**, 139–151 (2012).

81. Burra, M. *et al.* Enhanced intestinal absorption and bioavailability of raloxifene hydrochloride via lyophilized solid lipid nanoparticles. *Adv. Powder Technol.***24**, 393–402 (2013).

82. Harde, H., Das, M. & Jain, S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. *Expert Opin. Drug Deliv.***8**, 1407–1424 (2011).

83. Wang, Q. *et al.* Nanostructured lipid carriers as a delivery system of biochanin A. *Drug Deliv.***20**, 331–337 (2013).

84. Date, A. A. & Nagarsenker, M. S. Single-step and low-energy method to prepare solid lipid nanoparticles and nanostructured lipid carriers using biocompatible solvents. *Eur. J. Pharm. Res.***1**, 12–19 (2019).

85. Date, A. A., Vador, N., Jagtap, A. & Nagarsenker, M. S. Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: Fabrication, characterization and evaluation for oral drug delivery. *Nanotechnology***22**, 275102 (2011).

86. Kaur, I. P., Bhandari, R., Bhandari, S. & Kakkar, V. Potential of solid lipid nanoparticles in brain targeting. *J. Control. Release***127**, 97–109 (2008).

87. Montenegro, L. *et al.* From nanoemulsions to nanostructured lipid carriers: A relevant development in dermal delivery of drugs and cosmetics. *J. Drug Deliv. Sci. Technol.***32**, 100–112 (2016).

88. López-García, R. & Ganem-Rondero, A. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC): Occlusive Effect and Penetration Enhancement Ability. *J. Cosmet. Dermatological Sci. Appl.***05**, 62–72 (2015).

89. Martins, S., Tho, I., Souto, E., Ferreira, D. & Brandl, M. Multivariate design for the evaluation of lipid and surfactant composition effect for optimisation of lipid nanoparticles. *Eur. J. Pharm. Sci.***45**, 613–623 (2012).

90. Martins, S., Tho, I., Ferreira, D. C., Souto, E. B. & Brandl, M. Physicochemical properties of lipid nanoparticles: Effect of lipid and surfactant composition. *Drug Dev. Ind. Pharm.***37**, 815–824 (2011).

91. Teeranachaideekul, V., Boonme, P., Souto, E. B., Müller, R. H. & Junyaprasert, V. B. Influence of oil content on physicochemical properties and skin distribution of Nile red-loaded NLC. *J. Control. Release***128**, 134–141 (2008).

92. Jores, K., Haberland, A., Wartewig, S., Mäder, K. & Mehnert, W. Solid Lipid Nanoparticles (SLN) and oil-loaded SLN studied by spectrofluorometry and raman spectroscopy. *Pharm. Res.***22**, 1887–1897 (2005).

93. Teeranachaideekul, V., Souto, E. B., Junyaprasert, V. B. & Müller, R. H. Cetyl palmitate-based NLC for topical delivery of Coenzyme Q10 - Development, physicochemical characterization and in vitro release studies. *Eur. J. Pharm. Biopharm.***67**, 141–148 (2007).

94. Indu Pal Kaur, Bhandari, R. & Yakhmi, and J. V. *Lipids as Biological Materials for Nanoparticulate Delivery*. *Handbook of Nanomaterials Properties* (2014). doi:10.1007/978-3-642-31107-9

95. Chantaburanan, T., Teeranachaideekul, V., Chantasart, D., Jintapattanakit, A. &Junyaprasert, V. B. Effect of binary solid lipid matrix of wax and triglyceride on lipid crystallinity, drug-lipid interaction and drug release of ibuprofen-loaded solid lipid nanoparticles (SLN) for dermal delivery. *J. Colloid Interface Sci.***504**, 247–256 (2017).

96. Tran, T. H. *et al.* Preparation and Characterization of Fenofibrate-Loaded Nanostructured Lipid Carriers for Oral Bioavailability Enhancement. *AAPS PharmSciTech***15**, 1509–1515 (2014).

97. Hoppe, K. & Sznitowska, M. The Effect of Polysorbate 20 on Solubility and Stability of Candesartan Cilexetil in Dissolution Media. *AAPS PharmSciTech***15**, 1116–1125 (2014).

98. Nekkanti, V., Pillai, R., Venkateshwarlu, V. & Harisudhan, T. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles Solid oral dosage form incorporating drug nanoparticles. *Pharm. Dev. Technol.***14**, 290–298 (2009).

99. Nekkanti, V., Karatgi, P., Prabhu, R. & Pillai, R. Solid self-microemulsifying formulation for candesartan cilexetil. *AAPS PharmSciTech***11**, 9–17 (2010).

100. Bargoni, A. *et al.* Solid Lipid Nanoparticles in Lymph and Plasma After Duodenal Administration to Rats. *Pharm. Res.***15**, 745–750 (1998).

**Tables**

**Table (1):** Miscibility study of binary lipid mixtures with different surfactants

|  |  |  |
| --- | --- | --- |
| SL: LL in ratio | SAA  10 ml of 5% soln. | Transmittance ± SD % |
| Precirol® ATO 5:  Labrasol® ALF | Lutrol® F68 | 98.106 ± 5.3 |
| Lutrol® F127 | 97.972 ± 8.1 |
| Cremophore®EL | 94.756 ± 3.3 |
| Cremophore®RH | 81.847 ± 9.1 |
| Tween® 40 | 69.650 ± 1.8 |
| Tween® 80 | 65.850 ± 2.3 |
| Phospholibon® | 19.890 ± 7.3 |
| Compritol® ATO 888: Transcutol® HP | Lutrol® F68 | 97.324 ± 7.2 |
| Lutrol® F127 | 95.079 ± 1.4 |
| Cremophore®EL | 89.438 ± 1.3 |
| Cremophore®RH | 82.680 ± 6.3 |
| Tween® 40 | 67.435 ± 3.3 |
| Tween® 80 | 67.256 ± 7.2 |
| Phospholibon® | 10.350 ± 4.3 |
| GMS: CapryolTM 90 | Lutrol® F68 | 98.685 ± 5.2 |
| Lutrol® F127 | 95.004 ± 8.1 |
| Cremophore®EL | 86.475 ± 5.3 |
| Cremophore®RH | 78.185 ± 6.7 |
| Tween® 40 | 75.443 ± 6.3 |
| Tween® 80 | 69.481 ± 9.2 |
| Phospholibon® | 30.989 ± 8.3 |

**Table (2):** Miscibility study of binary lipid mixtures with combinations of surfactants

|  |  |  |
| --- | --- | --- |
| SL: LL in ratio | SAA Combination (1 :1)  10 ml of 5% soln. | Transmittance % |
| Precirol® ATO 5:  Labrasol® ALF | Lutrol® F68:  Tween® 40 | 53.8 ± 6.7 |
| Lutrol® F127:  Tween® 40 | 50.2 ± 9.5 |
| Lutrol® F68:  Cremophore® EL | 18.0 ± 7.3 |
| Lutrol® F127:  Cremophore® RH | 89.8 ± 8.5 |
| Compritol® ATO 888:  Transcutol® HP | Lutrol® F68:  Tween® 40 | 71.0 ± 5.2 |
| Lutrol® F127:  Tween® 40 | 59.0 ± 4.3 |
| Lutrol® F68:  Cremophore® EL | 54.1 ± 7.3 |
| Lutrol® F127:  Cremophore® RH | 26.7 ± 8.9 |
| GMS: CapryolTM 90 | Lutrol® F68:  Tween® 40 | 28.3 ± 4.4 |
| Lutrol® F127:  Tween® 40 | 23.2 ± 8.7 |
| Lutrol® F68:  Cremophore® EL | 98.2 ± 7.3 |
| Lutrol® F127:  Cremophore® RH | 96.7 ± 6.3 |

**Table (3):** Suggested formulae of CC-NLCs

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F No. | SL (70%) | | | LL (30%) | | | SAA (2.5%) of Total Formula  (g) | | | | Drug (5%) of Lipids  (mg) | Water  (92.5%)  (g) |
| **(5%) of Total Formula**  **(g)** | | | | | |
| **P** | **C** | **GMS** | **L** | **T** | **Cp** | **L F68** | **L F127** | **L F127 + Cr RH (1:1)** | **L F68 + Cr EL (1:1)** | **CC** |
| F1 | 3.5 |  |  | 1.5 |  |  | 2.5 |  |  |  | 250 | 92.5 |
| F2 | 3.5 |  |  | 1.5 |  |  |  | 2.5 |  |  | 250 | 92.5 |
| F3 | 3.5 |  |  | 1.5 |  |  |  |  | 2.5 |  | 250 | 92.5 |
| F4 |  | 3.5 |  |  | 1.5 |  | 2.5 |  |  |  | 250 | 92.5 |
| F5 |  | 3.5 |  |  | 1.5 |  |  | 2.5 |  |  | 250 | 92.5 |
| F6 |  |  | 3.5 |  |  | 1.5 | 2.5 |  |  |  | 250 | 92.5 |
| F7 |  |  | 3.5 |  |  | 1.5 |  | 2.5 |  |  | 250 | 92.5 |
| F8 |  |  | 3.5 |  |  | 1.5 |  |  |  | 2.5 | 250 | 92.5 |
| F9 |  |  | 3.5 |  |  | 1.5 |  |  | 2.5 |  | 250 | 92.5 |

SL = Solid lipid, LL = Liquid lipid, SAA = Surface active agent, P = Precirol®ATO 5, C = Compritol®ATO 888, GMS = Glyceryl Monostearate, L = Labrasol® ALF, T = Transcutol® HP, Cp = CapryolTM 90, L F68 = Lutrol® F68, L F127 = Lutrol® F127, Cr RH = Cremophore®RH, Cr EL = Cremophore®EL, CC = Candesartan Cilexetil.

**Table (4):** Particle size, polydispersity indices and zeta potential of CC-NLCs formulations

|  |  |  |  |
| --- | --- | --- | --- |
| Formula No. | PS (nm) | PDI | ZP (mV) |
| F1 | 280.6 ± 11.80 | 0.32 ± 0.01 | -17.8 ± 2.80 |
| F2 | 210.7 ± 9.10 | 0.32 ± 0.01 | -13.0 ± 2.30 |
| F3 | 118.6 ± 8.10 | 0.35 ± 0.03 | -13.9 ± 1.50 |
| F4 | 283.0 ± 9.90 | 0.22 ± 0.07 | -18.1 ± 2.40 |
| F5 | 196.5 ± 10.20 | 0.26 ± 0.05 | -18.7 ± 1.70 |
| F6 | 408.9 ± 11.50 | 0.28 ± 0.09 | -18.9 ± 1.90 |
| F7 | 141.8 ± 7.10 | 0.22 ± 0.07 | -23.8 ± 2.90 |
| F8 | 342.1 ± 13.80 | 0.21 ± 0.04 | -24.2 ± 3.50 |
| F9 | 114.6 ± 8.30 | 0.21 ± 0.04 | -27.3 ± 3.07 |

**Table (5):** Encapsulation efficiency and loading capacity of CC-NLCs formulations

|  |  |  |
| --- | --- | --- |
| Formula No. | E.E. (%) | L.C. (%) |
| F1 | 99.80 ± 2.50 | 1.03 ± 0.10 |
| F2 | 98.70 ± 3.40 | 1.12 ± 0.35 |
| F3 | 98.50 ± 2.70 | 1.32 ± 0.21 |
| F4 | 99.30 ± 2.25 | 0.55 ± 0.11 |
| F5 | 99.04 ± 2.35 | 0.82 ± 0.13 |
| F6 | 95.94 ± 3.45 | 3.92 ± 0.31 |
| F7 | 95.04 ± 3.40 | 4.82 ± 0.11 |
| F8 | 95.56 ± 2.50 | 4.30 ± 0.12 |
| F9 | 94.76 ± 2.44 | 5.10 ± 0.19 |

**Figures**

D:\ph d documents\Walid Ph.D EXPERIMENTAL\PhD Paper Word\FIGURES\SL .tif

**Figure (1):**Solubility study of CC in different solid lipids

D:\ph d documents\Walid Ph.D EXPERIMENTAL\PhD Paper Word\FIGURES\LL .tif

**Figure (2):**Solubility study of CC in different liquid lipids

D:\ph d documents\Walid Ph.D EXPERIMENTAL\PhD Paper Word\FIGURES\ps, pdi combo.tif

**Figure (3):** Mean particles size and polydispersity index of CC-NLCs formulations

D:\ph d documents\Walid Ph.D EXPERIMENTAL\PhD Paper Word\FIGURES\ZETA.tif

**Figure (4):** Zeta potential of CC-NLCs formulations

D:\ph d documents\Walid Ph.D EXPERIMENTAL\PhD Paper Word\FIGURES\EE%.tif

**Figure (5):** Encapsulation efficiency and loading capacity of CC-NLCs formulations